<DOC>
	<DOCNO>NCT00152594</DOCNO>
	<brief_summary>The purpose study determine whether voriconazole effective antifungal prophylaxis patient undergo chemotherapy acute myelogenous leukemia ( AML ) . Hypothesis : Voriconazole superior placebo prophylaxis lung infiltrate day 21 start induction chemotherapy .</brief_summary>
	<brief_title>Voriconazole Placebo Prophylaxis Lung Infiltrates Patients Undergoing Induction Chemotherapy Acute Myelogenous Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Voriconazole</mesh_term>
	<criteria>1 . Newly diagnose relapse , de novo secondary AML 2 . First induction chemotherapy cycle 3 . Expected neutropenic phase minimum duration 10 day 4 . Age &gt; = 18 year 5 . Legally sign consent form 1 . Known proven , probable possible invasive fungal infection randomization patient history 2 . Computed tomography ( CT ) sign fungal infection accord European Organisation Research Treatment Cancer ( EORTC ) /Mycosis Study Group ( MSG ) criterion , i.e . infiltrate ( Ascioglu , et al 2002 ) 3 . Any current fever unless explain noninfectious cause 4 . Antibacterial prophylaxis TMP/SMX 5 . Liver function test [ LFT ] ( AST/ALT/bilirubin ) 3x upper normal limit 6 . Subjects receive discontinue one follow drug least 24 hour prior randomization : Drugs know possibility QTc prolongation ( e.g . terfenadine , astemizole , cisapride , pimozide , quinidine ) ; Drugs whose plasma level may increase voriconazole therapy ( e.g . sulfonylurea , ergot alkaloid , sirolimus , vinca alkaloid ) . 7 . Subjects receive follow drug within 14 day prior randomization : potent inducer hepatic enzyme reduce voriconazole level ( e.g . rifampicin , carbamazepine barbiturate ) 8 . Concomitant therapy absorbable antifungal 9 . Patient diagnosis acute hepatitis cirrhosis due cause 10 . Known hypersensitivity contraindication voriconazole 11 . Patient unwilling unable comply protocol . 12 . Diseases disability prevent patient participate trial 13 . Females childbearing potential without negative serum pregnancy test baseline within 72 hour prior start study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2006</verification_date>
</DOC>